Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
- 1 November 1993
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (21) , 9847-9851
- https://doi.org/10.1073/pnas.90.21.9847
Abstract
As the action of aldose reductase (EC 1.1.1.21) is believed to be linked to the pathogenesis of diabetic complications affecting the nervous, renal, and visual systems, the development of therapeutic agents has attracted intense effort. We report the refined 1.8 angstrom x-ray structure of the human holoenzyme complexed with zopolrestat, one of the most potent noncompetitive inhibitors. The zopolrestat fits snugly in the hydrophobic active site pocket and induces a hinge-flap motion of two peptide segments that closes the pocket. Excellent complementarity and affinity are achieved on inhibitor binding by the formation of 110 contacts (less-than-or-equal-to 4 angstrom) with 15 residues (10 hydrophobic), 13 with the NADPH coenzyme and 9 with four water molecules. The structure is key to understanding the mode of action of this class of inhibitors and for rational design of better therapeutics.Keywords
This publication has 11 references indexed in Scilit:
- THE CRYSTAL STRUCTURE OF THE ALDOSE REDUCTASE NADPH BINARY COMPLEXPublished by Worldwide Protein Data Bank ,1994
- Molecular cloning of testicular 20.alpha.-hydroxysteroid dehydrogenase: Identity with aldose reductaseBiochemistry, 1993
- Aldose reductase inhibitors: Recent developmentsPublished by Springer Nature ,1993
- Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303.Journal of Biological Chemistry, 1992
- An Unlikely Sugar Substrate Site in the 1.65 Å Structure of the Human Aldose Reductase Holoenzyme Implicated in Diabetic ComplicationsScience, 1992
- Novel NADPH-binding domain revealed by the crystal structure of aldose reductaseNature, 1992
- Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congenersJournal of Medicinal Chemistry, 1991
- ALDOSE REDUCTASE FROM HUMAN PSOAS MUSCLE - PURIFICATION, SUBSTRATE-SPECIFICITY, IMMUNOLOGICAL CHARACTERIZATION, AND EFFECT OF DRUGS AND INHIBITORS1989
- The role of aldose reductase in the development of diabetic complicationsMedicinal Research Reviews, 1988
- PHARMACOPHORE REQUIREMENTS OF THE ALDOSE REDUCTASE INHIBITOR SITE1983